# Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

> **NCT02082236** · PHASE1 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment Arm A: Sufenta®
- **DRUG:** Treatment B: Sufentanil SSM 30 mcg
- **DRUG:** Treatment C: SSM 15 mcg
- **DRUG:** Treatment D: SSM 30 mcg

## Key facts

- **NCT ID:** NCT02082236
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082236, "Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02082236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*